On April 15, 2013, the Supreme Court will hear oral arguments in the Myriad Genetics v. Association for Molecular Pathology litigation. The patent world is watching, particularly those who focus on emerging technologies. On March 14, 2013, the NanoBusiness Commercialization Association filed a brief in support of Myriad Genetics (brief prepared by Foley & Lardner, LLP). In addition to arguing that the patent claims should be patent eligible, which is the essence of the case, the brief also argues that patents do not preempt others from experimenting on, improving upon, or designing around a patented invention. With today being the first day of the new first-to-file regime, patent lawyers of all stripes are busy these days keeping up with dramatic changes to the patent system. The Supreme Court could use the Myriad case to establish a new paradigm for patent eligibility. Stay tuned.
Related Insights
24 January 2025
Foley Viewpoints
Incoming Environmental Protection Agency (EPA) Personnel and Impact on Enforcement
To nobody’s surprise, it is already evident that President Trump’s second term will mark a significant shift in environmental regulation and policy from the Biden Administration.
24 February 2025
Events
Corporate Integrity Agreements: Independent Review of Organizations and the Office of the Inspector General
Foley partner Judy Waltz, chair of the firm’s Health Care Practice Group, is speaking in the Health Care Compliance Board & Compliance Committee Conference in the panel “Corporate Integrity Agreements: Independent Review of Organizations and the Office of the Inspector General.”
24 January 2025
Foley Viewpoints
Corporate Transparency Act Enforcement Remains Paused
On January 23, 2025, the U.S. Supreme Court issued a stay of the nationwide preliminary injunction issued by a federal district court in Texas in December 2024 in the Texas Top Cop Shop litigation.